share_log

Needham Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $100

Needham Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $100

Needham確認買入 Intra-Cellular Therapies,將價格目標提高至100美元。
Benzinga ·  07/22 05:29  · 評級/大行評級

Needham analyst Ami Fadia maintains Intra-Cellular Therapies (NASDAQ:ITCI) with a Buy and raises the price target from $94 to $100.

Needham分析師Ami Fadia稱納斯達克股票ITCI爲買入,將目標股價從94美元上調至100美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論